BusinessGlobal Blood Therapeutics to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 8:13 PM UTC
BusinessGlobal Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in MarchBy Nasdaq OMXMar 1, 2017, 9:05 PM UTC
BusinessGlobal Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional SharesBy Nasdaq OMXFeb 27, 2017, 9:05 PM UTC
BusinessGlobal Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic ConditionsBy Nasdaq OMXFeb 16, 2017, 9:05 PM UTC
BusinessGlobal Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry LettersBy Nasdaq OMXFeb 14, 2017, 1:31 PM UTC
BusinessGlobal Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry LettersBy Nasdaq OMXFeb 14, 2017, 1:31 PM UTC
BusinessGlobal Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell DiseaseBy Nasdaq OMXJan 18, 2017, 1:30 PM UTC
BusinessGlobal Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 3, 2017, 9:06 PM UTC
